Can men receiving ADT triplet therapy (LHRH agonist or antagonist plus docetaxel and a second-line androgen-axis drug such as abiraterone or enzalutamide) achieve erections sufficient for sexual intercourse?

Erectile Function and Sexual Activity During ADT Triplet Therapy

Men receiving ADT triplet therapy will almost certainly experience severe erectile dysfunction and will be unable to achieve erections sufficient for penetrative intercourse without medical intervention. The combination of androgen deprivation with additional androgen-axis drugs creates profound testosterone suppression that eliminates the hormonal foundation necessary for erectile function.

The Physiological Reality

ADT—whether used alone or as part of triplet therapy—suppresses testosterone to castrate levels (<50 ng/dL), which fundamentally impairs both libido and erectile function 1. The addition of second-generation androgen receptor pathway inhibitors (abiraterone, enzalutamide, darolutamide) or chemotherapy to ADT does not improve sexual function; rather, these agents maintain or intensify androgen suppression 2.

Key physiological effects:

• Loss of sexual desire (libido) is typically the first and most profound effect
• Erectile dysfunction occurs due to both hormonal deprivation and loss of sexual interest
• Even if erections could be mechanically achieved, the desire for sexual activity is typically absent

Evidence on Sexual Function During ADT

The available evidence paints a stark picture:

• In one study of men on ADT, only 2 out of 62 previously sexually active men remained sexually active during treatment, though 29 maintained some interest 3
• Only 1 patient had erections sufficient for penetrative intercourse 3
• Median sexual satisfaction was 0 on a 0-10 scale 3
• Quality of life measures show that erectile function and mental health are significantly impaired during continuous ADT 4, 5

Treatment Options and Their Limitations

While erectile dysfunction treatments exist, their effectiveness is severely limited during ADT:

PDE5 inhibitors (sildenafil, tadalafil, vardenafil):

• Response rates of only 33-80% in ADT patients, with 44% responding to PDE5 inhibitor monotherapy 6
• These medications require some baseline testosterone and sexual stimulation to work effectively 7
• With castrate testosterone levels, efficacy is substantially reduced

Alternative interventions:

• Intracavernosal prostaglandin injections
• Vacuum erection devices
• Penile prosthesis (surgical option)
• Combination therapies 1

Critical limitation: Even when these interventions can mechanically produce erections, the loss of libido from testosterone suppression means most men lack interest in sexual activity 3.

Important Counseling Points

Before starting triplet therapy, patients should understand:

1. Sexual function will be severely impaired during treatment, affecting both desire and ability
2. Recovery is uncertain and depends on treatment duration and individual factors 8
3. Younger age is associated with better recovery after ADT discontinuation 8
4. GnRH antagonists (like relugolix) allow faster testosterone recovery than agonists (like leuprolide) if ADT is discontinued 8
5. Extended ADT courses (>12 months) reduce likelihood of testosterone recovery 8

Alternative Sexual Expression

Guidelines emphasize that sexuality extends beyond penetrative intercourse 1:

• Orgasm can occur without erection or ejaculation
• Emotional intimacy and connection with partners remain possible
• Many men report that maintaining emotional connection with their partner becomes the primary motivator for any sexual activity 3

Clinical Approach

For men considering triplet therapy:

1. Discuss sexual function expectations upfront before treatment initiation
2. Assess baseline erectile function and relationship factors
3. Consider referral to sexual health specialist or urologist for comprehensive counseling 1
4. Discuss couple-based interventions as sexual dysfunction affects both partners 1
5. Plan for potential interventions if patient desires to maintain some sexual activity

Common pitfall: Failing to address sexual function proactively leads to patient distress and relationship strain. These conversations must happen before treatment starts, not after dysfunction develops.

The Bottom Line

While mechanical erections may be achievable with aggressive medical intervention (injections, devices, or prosthesis), the profound loss of libido from triplet therapy means most men will have neither the desire nor the ability for sexual intercourse during active treatment. Recovery of function after treatment cessation is variable and depends on multiple factors including age, treatment duration, and type of ADT used 8.